PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re appli	cation of:)
	GRUBER et al)
Filed:	HEREWITH)
For:	ANTITHROMROTIC T	THROMRIN VARIANTS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicant hereby voluntarily discloses the reference listed on the attached Form PTO-1449 to the Assistant Commissioner for Patents. References (A-AA) were cited in a prior application relied upon by the above-identified application for an earlier filing date. The prior application relied upon is Application Serial No. 10/165,442, filed on June 7, 2002. It is specified in 37 CFR 1.98(d) that a "copy of any patent, publication or other information listed in an information disclosure statement is not required to be provided if it was previously cited by or submitted to the Office in a prior application, provided the prior application is properly identified in the statement and relied upon for an earlier filing date under 35 USC 120." Therefore please review the parent case for references (A-AA).

Applicant further reserves the right to establish the patentability of the claimed invention over any of the listed information should they be applied as references, and/or to prove that some of the cited information may not be prior art, and/or to prove that some of the cited information may not be enabling for the teachings they purport to offer. This statement further should not be construed as the representation that an exhaustive search has been made, or that the information cited herewith is material, or that there does not exist information more material to the examination of the present Application. The Examiner is specifically requested not to rely solely

on the information submitted herein. On the contrary, the Examiner is requested to conduct an independent and thorough review of the information, and to form independent opinions as to their significance.

It is respectfully requested that the Examiner initial and return copies of the enclosed PTO-1449 and to indicate in the official file wrapper of the above-identified patent application that each item of the cited information has been considered.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to account no. 09-0528.

10/3//2003

David J. Hayzer, Ph.D.

Attorney for Applicant Registration No. 43,329

Womble Carlyle Sandridge & Rice, PLLC

P.O. Box 7037

Atlanta, GA 30357-0037

(404) 872-7000 (Telephone)

(404) 870-2413 (Facsimile)

Customer ID No.: 26158

Docket No.: **E056 1071.1**

Form PTO-1449 INFORMATION DISCLOSURE CITATION			Attorney Docket No. Serial No. E056 1071.1 Applicants: GRUBER et al								
						Filing Dat FILED HE			Group Art Unit		
				U.S.	PATENT DOCU	MENTS			_		
Examiner Initials	Item		cument mber	Date	Name	•	Class	Subclass	Filing Date If Appropriate		
	<u>!</u>		FO	REIC	ON PATENT DO	CUMENTS					
		Document Number		Date	Countr	у	Class	Subclass	Translation		
									Yes No		
	لــــا)	OT1	HER DOCUME	NTS	(Including Author,	Title. Date. Pe	rtinent P	ages. etc.)	L I		
SS		A	Arosio, et al Mut	ation (of W215 Compromise.	s Thrombin Clea			but Not of		
<u> </u>		В	Bernard, et al Eff	Bernard, et al Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis - N. Engl. J. Med. 344, 699-709 (2001)							
		С	Bonniec, et al Glu-192 → Gln substitution in thrombin mimics the catalytic switch induced by thrombomodulin - Proc. Natl. Acad. Sci. 88, 7371-7375 (1991)								
		D	Bouton, et al Role of the thrombin insertion loop 144-155, Study of thrombin mutations W148G, K154E and a thrombin-based synthetic peptide - Eur. J. Biochem. 229, 526-532 (1995)								
		Е	Cantwell & Di Cera - Rational Design of a Potent Anticoagulant Thrombin - Journal of Biological Chemistry 275, 39827-39830 (2000)								
		F	Di Cera - Anticoag	Di Cera - Anticoagulant Thrombins - Trends in Cardiovascular Medicine 8, 340-350 (1998)							
•		G	Gibbs, et al Conversion of thrombin into an anticoagulant by protein engineering – Nature 378, 413-416 (1995)								
		Н	Gresele, et al Activated Human Protein C Prevents Thrombin-induced Thromboembolism in Mice – Journal for Clinical Investigation 101, 667-676 (1998)								
		I	Gruber, et al The Thrombin Mutant W215A/E217A Shows Safe and Potent Anticoagulant and Antithrombotic Effects in Vivo - Journal of Biological Chemistry 277, 27581-27584 (2002)								
		J	Gruber, et al Direct Detection of Activated Protein C in Blood from Human Subjects - Blood 79 2340-2348 (1992) Gruber, et al Inhibition of Platelet-Dependent Thrombus Formation by Human Activated Protein C in a Primate Model - Blood 73, 639-642 (1989)								
		K									
		L	Guinto, et al Unexpected crucial role of residue 225 in serine proteases - Proc. Natl. Acad. Sci. USA 96, 1852-1857 (1999)								
4	7	М	Hanson, et al Anti in Primates – Journ	ithrom al for	botic Effects of Thron Clinical Investigation	nbin-induced Ac 92, 2003-2012	tivation ((1993)	of Endogen	ous Protein C		
pplicant.	tion if	not i	in conformance and i	red, w	hether or not citation nsidered. Include cop	is in conforman	ce with N	APEP § 609 communica	Draw line tion to the		
EXAMINE	R'S SI	GN/	SHERIDA	N SW	OPE, Ph.D. MINER Patent and Trac	ONSIDERED:	0	207	0.0		

Form PTO-1449				Attorney I E056 1071	Serial No.								
INF	ORM	IAT	TON DISCLO	SURE	CITATI	ON	Applicants GRUBER						
(Use several sheets if necessary)				Filing Date: FILED HEREWITH			Group Art Unit						
				U.S.	PATENT	DOCU	MENTS						
Examiner Initials	iner Item Document Als Number				ate Name Class Subclass						Filing Date If Appropriate		
		<u> </u>	FC	REIC	SN PATE	NT DO	CUMENTS					<u> </u>	
			cument	Date Coun			у .	Class	Sul	oclass	Transla	tion	
		Nu	mber ·								Yes	No	
	<u> </u>	_				•	•		<u> </u>		<u> </u>		
	1		HER DOCUM	•									
$\langle X \rangle$		N	Harker, et al Ex IV-41-IV-55 (199	-	ntal Arterial	Thrombo	sis in Nonhuma.	n Primal	es - (Circulat	ion 83,		
<u> </u>		0	Ishii, et al Thro Investigation 76,	mbomo		ent in Hu	man Plasma and	d Urine -	- Jou	mal for	Clinical		
		P	Kogan, et al Pr Thrombus Forma	otein C	Activator fre								
	+	Q	Leung, et al Dis	(1993) Leung, et al Dissociation of Thrombin's Substrate Interactions Using Site-Directed Mutagenesis									
		R	- Trends in Cardi Marder, et al Pi	ovascul asmin I	ar Medicine nduces Loca	10, 89-92 Il Thromb	2 (2000) olysis without C	ausing F	lermo	orrhage	:: A		
	•		Comparison with 745 (2001)										
		S	Martinoli, et al Thrombosis Rese				say Using Prote	c, A No	vel Pr	otein C	Activator	••	
		T	McBane, et al A	Intithro	mbotic Actio	n of Ende	ogenous Porcine	Protein	C Ac	tivated	with a La	tent	
		υ	Porcine Thrombin Preparation - Thrombosis Haemostasis 74, 879-885 (1995) Richardson, et al Enhancing protein C interaction with thrombin results in a clot-activated anticoagulant - Nature 360, 261-264 (1992)										
		v	Sheehan, et al Mutagenesis of Thrombin Selectively Modulates Inhibition by Serpins Heparin Cofactor II and Antithrombin III - The Journal of Biological Chemistry 268, 3639-3645 (1993)										
		w	Takahashi, et al Soluble Thrombomodulin Purified from Human Urine Exhibits a Potent Anticoagulant Effect In Vitro and In Vivo - Thrombosis Haemostasis 73, 805-811 (1995)										
		x	Taylor, et al Protein C Prevents the Coagulopathic and Lethal Effects of Escherichia coli Infusion in the Baboon – Journal for Clinical Investigation 79, 918-925 (1987)										
		Y	Y Tsiang, et al Protein Engineering Thrombin for Optimal Specificity and Potency of Anticoagulant Activity in Vivo - Biochemistry 35, 16449-16457 (1996)										
		Z	Vindigni, et al I Biochemistry 35,	Release 4417-44	of Fibrinope 126 (1996)	ptides by	the Slow and F	ast Form	s of T	hromb	in -		
4	7	AA	Wu, et al Single binding activities	amino of huma	acid substitu in thrombin	itions diss - Proc. Na	sociate fibrinoge atl. Acad. Sci. 8	en-clottin 8, 6775-6	g and 5779 (l throm (1991)	bomodulii	7-	
through cita applicant.	tion if	not	ial if citation considing conformance and	d not co	nsidered. In	clude cop	y of this form w	ith next	comr	nunicat	ion to the	ne	
EXAMINE	R'S S	GN/	ATUSHERIDAN SI PATENT EX	WOPE,	Ph.D.	DATE C	ONSIDERED:	02	07	0 8			



Form PTO-1449

Attorney Docket No. E056 1071.1

Serial No. 10/699,393

INFORMATION DISCLOSURE CITATION

Applicant GRUBER et al

						GRUBER et al						
		(Use several sh	ary)	Filing October		Group						
	٧		U.S.	PATENT DOCU	MENTS							
Examiner Initials	Item	Document Number	Date	Date Nan		Class	Subclass		Filing Date If Appropriate			
85	AA	6,110,721	08/2000	Gibbs et al	ibbs et al			1				
			FOREI	GN PATENT DO	CUMENTS		,					
		Document Number	Date	Countr	ry	Class	Subclass		Translation			
		Nullipel							Yes	No		
									•			
	\$											
		OTHER DO	CUMENTS	(Including Author, I	Title, Date, Per	tinent Pa	ges, etc	:.)				
			-,	·								
				ether or not citation is Include copy of this fo						rough		

EXAMINER'S SIGNATURE RIDAN SWOPE, Ph.D. PATENT EXAMINER

DATE CONSIDERED:

020706

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE